BinDawood Holding Co. (BDH)

2Q2026 First Look

Growing Ecosystem Seeks Synergies with Grocery Business

August 13, 2026

Upside to Target Price	(0.7%)	Rating	Neutral
Expected Dividend Yield	1.8%	Last Price	SAR 4.53
Expected Total Return	1.1%	12-mth target	SAR 4.50

Market Data	
52-week high/low	SAR 5.92 / 4.10
Market Cap	SAR 5,178 mln
Shares Outstanding	1,143 mln
Free-float	26.54%
12-month ADTV	844,534
Bloomberg Code	BINDAWOO AB



BDH	2Q2026	2Q2025	Y/Y	1Q2026	Q/Q	RC Estimate
Sales	1,643	1,474	11%	1,811	(9%)	1,555
Gross Profit	576	533	8%	580	(1%)	498
Gross Margins	35%	36%		32%		32%
Operating Profit	101	80	26%	110	(8%)	82
Net Profit	50	52	(4%)	70	(29%)	50

(All figures are in SAR mln)

- BDH reported 2Q26 revenue of SAR 1,643 mln (+11% Y/Y, -9% Q/Q), slightly above our SAR 1,555 mln estimate, and gross profit of SAR 576 mln (+8% Y/Y, -1% Q/Q), materially above our SAR 498 mln, driven by gross margin of 35% being higher than our 32% forecast. Operating profit of SAR 101 mln (+26% Y/Y, -8% Q/Q) was also above our SAR 82 mln forecast. Net profit (attributable to shareholders) of SAR 50 mln (-4% Y/Y, -29% Q/Q) matched our SAR 50 mln estimate. We also note that growth was carried by grocery expansion, a full period of Toy Triangle and one month of Vaza Foods.
- Consolidated net profit rose +5.3% Y/Y to SAR 53.2 mln, but the attributable figure fell -4% to SAR 50 mln: non-controlling interests took SAR 3.6 mln in 2Q26 versus SAR (1.3) mln in 2Q25, an increase of roughly SAR 5 mln. Below the operating line, costs absorbed SAR 48 mln versus SAR 30 mln in 2Q25, driven by lease liabilities, acquisition financing and lower finance income. We would remind investors that the +306 bps Q/Q gross margin increase was supported by the recognition of pharmacy rebates and target incentives.
- The operating story is intact — 103 grocery and 209 pharmacy stores, Vaza Foods consolidated from 1 June, Wonder Bakery expected in 3Q26 and the first Riyadh store opened in July 2026 — but earnings attributable to shareholders were flat over the 1H26 vs. 1H25 periods, at SAR 119.7 mln (+0.6% Y/Y), while the acquisition program is debt-funded and the minority share is rising. Wasfaty modifications continue to weigh on pharmacy revenue as well, consistent with what we observe across our pharmacy retail coverage. We remain Neutral and hold our target price while we wait for the financials to review the net debt position.

Brennan Eatough
brennan.eatough@riyadcapital.com
+966-11-203-6808

الرياض المالية
Riyad Capital

Disclaimer

Stock Rating

Buy	Neutral	Sell	Not Rated
Expected Total Return Greater than +15%	Expected Total Return between -15% and +15%	Expected Total Return less than -15%	Under Review/Restricted

The expected percentage returns are indicative, stock recommendations also incorporate relevant qualitative factors

For any feedback on our reports, please contact research@riyadcapital.com

الرياض المالية
Riyad Capital